Ä¿¹Â´ÏƼ

¾¾¾ÆÀ̹ÙÀÌ¿À´Â ¹ÏÀ½°ú ½Å·Ú¸¦ ¹ÙÅÁÀ¸·Î
±Í»çÀÇ ±¹³», ÇØ¿ÜÁøÃâÀÇ ÆÄÆ®³Ê°¡ µÇ°Ú½À´Ï´Ù.

Ä¿¹Â´ÏƼ

  • Ȩ
  • Ä¿¹Â´ÏƼ
  • ÀÚ·á½Ç

ÀÚ·á½Ç

Á¦¸ñ Preclinical cases to USA ,Reference
ÀÛ¼ºÀÚ °ü¸®ÀÚ
ÀÛ¼ºÀÏÀÚ 2026-05-07
Á¶È¸¼ö 37




  ÀÌ¹Ì ¹Ì±¹ÁøÃâÇÑ Case studyµéÀ»(Oncology°ü·Ã´Ù¼ö) º¸À¯Çϰí ÀÖ½À´Ï´Ù.


 (Preformulation service platform)


  Preclinical (Medical chemistry, Invivo Phamacology, Toxicology)---Preformulation Accelerate the IND filing of small molecular
    drug candidate.


    --CMC(Chemistry development, Pharmaceutical development ,Analytical development))




* In vivo pharmacology platform (Oncology), For example..


     1)Liver cancer: 16 human cancer cell lines


     2) Hepa1-6/H22 , mouse cancer cell lines.




* Early pk/efficacy/toxicology formulation development


* Recommedation of Clinical formulation strategy






Other cases will give after CDA, perfectly.
   


  ´Ù¾çÇÑ ºÐ¾ß¿¡¼­ °¡´ÉÇϸç, ´ë·«ÀûÀ¸·Î´Â


   1) Oncology: PDX, PDO & PDC bank. New drug R&D service


   2) Non-Oncology: New drug development , Transgenic mice platform


   3) Analytics: Biochemical service, Pre-clinical sample analysis, Preformulation service.


   4) Lab Animal Capacity:(Numbers opens after CDA,
 :    00,000Mice/Rats, 000 Monkeys, 000 Dogs,000 Rabbits, 000 Guinea Pigs)


¹Ì±¹ÁøÃâÀ» Àú·ÅÇÏ°í ºü¸£°ÔÇϽðí,ÀÌÈÄ IITµîÀ¸·Î Ȱ¿ëÇÏ¿© CMO, Clinical µî ºñ¿ëÀý°¨,TIimeline Àý°¨ÇϽðí
  ¿øÇϽô ´Ü°è±îÁö ºü¸£°Ô °¡½Ç¼ö ÀÖ½À´Ï´Ù.
 
÷ºÎÆÄÀÏ